

5.4 Literaturverzeichnis

- 1 Acton PD, Kung MP, Mu M, et al. SPECT Imaging of Serotonin Transporters in the non-human Primate Brain with the selective tracer [¹²³I]IDAM. Eur J Nucl Med 1999; 26: 854-61.
- 2 Acton PD, Mu M, Plossl K, et al. Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with [(123)I]ODAM. Eur J Nucl Med 1999; 26:1359-62.
- 3 Acton PD, Choi SR, Hou C, Plossl K, Kung HF. Quantification of serotonin transporters in nonhuman primates using [(123)I]ADAM and SPECT. J Nucl Med 2001; 42:1556-62.
- 4 Aktories K, Förstermann U, Hofmann FB, Starke K, Förstermann U, Rummel W. Allgemeine und spezielle Pharmakologie und Toxikologie. Urban & Fischer, 2004
- 5 Anderson GM, Horne WC. ctivators of protein kinase C decrease serotonin transport in human platelets. Biochem Biophys Acta 1992;1137:331-7.
- 6 Asenbaum S, Zettining G, Dudczak R, 123I-ADAM SPECT: a new method for investigating the serotonin transporters in humans. Eur J Nucl Med Mol Imaging 2003; 30(suppl), A 309
- 8 Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V. "Serotonin depression"--a biochemical subgroup within the affective disorders? Science 1976;191:478-80.
- 9 Balkovetz DH, Tirupathi C, Leibach FH, Mahesh VB, Ganapathy V. Evidence for an imipramine-sensitive serotonin transporter in human placental brush-border membranes, J Biol Chem 1989;264:2195-8.
- 10 Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology 2002;163:20-5.
- 11 Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002;22:6766-72.
- 12 Berger M; Psychiatrie und Psychotherapie, Urban & Fischer Verlag. 2002

- 13 Bergstrom KA; Kuikka JT, Ahonen A, Vanninen E. [123I] beta-CIT, a tracer for dopamine and serotonin re-uptake sites: preparation and preliminary SPECT studies in humans. *J Nucl Biol Med* 1994;38(4Suppl1):128-31.
- 14 Bergstrom KA, Halldin C, Hall H, et al. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. *Eur J Nucl Med* 1997;24(6):596-601.
- 15 Blakely RD, Berson HE. Molecular biology of serotonin receptors and transporters. *Clin Neuropharmacol* 1992;15(Suppl1):351A-2A.
- 16 Blazer DG 2nd, Hybels CF. Origins of depression in later life. *Psychol Med* 2005;35:1241-52.
- 17 Boja JW, Mitchell WM, Patel A, et al. High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain. *Synapse* 1992;12:27-36.
- 18 Booij J, de Win MM. Brain kinetics of the new selective serotonin transporter tracer [(123)I]ADAM in healthy young adults. *Nucl Med Biol* 2006;33:185-91.
- 19 Briley MS, Fillion G, Beaudoin D, Fillion MP, Langer SZ. 3H-imipramine binding in neuronal and glial fractions of horse striatum. *Eur J Pharmacol* 1980;64:191-4.
- 20 Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. *Therapie* 2004;59:5-12.
- 21 Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. *J Neural Transm Gen Sect* 1993;94:137-46.
- 22 Buchert R, Schulze O, Wilke F, Berding G, Thomasius R, Petersen K, Brenner W, Clausen M. Is Correction for Age Necessary in SPECT or PET of the Central Serotonin Transporter in Young, Healthy Adults? *J Nucl Med* 2006;47:38-42.
- 23 Casey DA. Depression in the elderly. *South Med J*. 1994;87:559-63.
- 24 Catafau AM, Perez V, Penengo MM, Bullich S, et al. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. *J Nucl Med* 2005;46:1301-9.
- 25 Chalon S, Bronquard C, Vercouillie J, et al. ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models. *Synapse* 2004;52:136-42.

- 26 Chang. A method for attenuation correction in computed tomography. *IEEE Trans Nucl Sci* 1978;25:638-43.
- 27 Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. *Arch Gen Psychiatry* 1981;38:1160-80.
- 29 Choi SR, Hou C, Oya S, et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. *Synapse* 2000;38:403-12.
- 30 Coppen A. Defects in monoamine metabolism and their possible importance in the pathogenesis of depressive syndromes. *Psychiatr Neurol Neurochir* 1969;72:173-80.
- 31 Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. *Experientia* 1964;20:398-9.
- 32 Dahlstrom M, Ahonen A, Ebeling H, Torniaainen P, Heikkila J, Moilanen I. Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. *Mol Psychiatry* 2000;5:514-22.
- 33 de Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. *Neuropsychopharmacology* 2005;30:996-1005.
- 34 Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. *Lancet* 2006;367:153-67.
- 35 Eggers B, Hermann W, Barthel H, Sabri O, Wagner A, Hesse S. The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson's disease. *J Neurol* 2003;250:576-80.
- 36 Erlandsson K, Sivananthan T, Lui D, et al. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. *Eur J Nucl Med Mol Imaging* 2005;32:1329-36.
- 37 Erspamer V. Observations of the metabolism of endogenous 5-hydroxytryptamine (enteramine) in the rat. *Experientia* 1954;10:471-2.
- 38 Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. *J Clin Psychiatry* 1999;60:824-30.

- 39 Foye, W.O., T.L. Lemke and D.A. Williams. Principles of Medicinal Chemistry. Williams & Wilkins. Fourth Edition, 1995
- 40 Frankle WG, Huang Y, Hwang DR, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. *J Nucl Med* 2004;45:682-94.
- 41 Gelenberg AJ, Chesen CL. How fast are antidepressants? *J Clin Psychiatry* 2000;61:712-21.
- 42 Gelernter J, Pakstis AJ, Kidd KK. Linkage mapping of serotonin transporter protein gene SLC6A4 on chromosome 17. *Hum Genet* 1995;95:677-80.
- 43 Gutierrez B, Pintor L, Gasto C, et al. Variability in the serotonin transporter gene and increased risk for major depression with melancholia. *Hum Genet* 1998;103:319-22.
- 44 Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 1967;6:278-96.
- 45 Heils A, Teufel A, Petri S, et al. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. *J Neural Transm Gen Sect* 1995;102:247-54.
- 46 Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, Felix R, Uebelhack R, Plotkin M. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. *J Neural Transm* 2006;113(5):659-70.
- 47 Hesse S, Barthel H, Murai T, et al. Is correction for age necessary in neuroimaging studies of the central serotonin transporter? *Eur J Nucl Med Mol Imaging* 2003;30:427-30.
- 48 Hiltunen J, Akerman KK, Kuikka JT, et al. Iodine-123 labeled nor-beta-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. *Eur J Nucl Med* 1998;25:19-23.
- 49 Horschitz S, Hummerich R, Schloss P. Structure, function and regulation of the 5-hydroxytryptamine (serotonin) transporter. *Biochem Soc Trans* 2001;29:728-32.
- 50 Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. *Eur J Nucl Med* 2000;27:1719-22.
- 51 Huang Y, Hwang DR, Zhu Z, et al. Synthesis and pharmacological characterization of a new PET ligand for the serotonin transporter: [11C]5-bromo-2-

[2-(dimethylaminomethylphenylsulfanyl)]phenylamine ([¹¹C]DAPA). *Nucl Med Biol* 2002;29:741-51.

52 Huang Y, Hwang DR, Narendran R, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [¹¹C]McN 5652, [¹¹C]ADAM, [¹¹C]DASB, [¹¹C]DAPA, and [¹¹C]AFM. *J Cereb Blood Flow Metab* 2002;22:1377-98.

53 Huang WS, Ma KH, Cheng CY, et al. Imaging serotonin transporters with ¹²³I-ADAM brain SPECT in healthy non-human primates. *Nucl Med Commun* 2004;25:515-9.

54 Huang Y, Hwang DR, Bae SA, et al. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [¹¹C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([¹¹C]AFM). *Nucl Med Biol* 2004;31:543-56.

55 Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). *Nord J Psychiatry* 1993 ;47(Suppl30):5-12.

56 Hyttel J, Arnt J, Sanchez C. The pharmacology of citalopram. *Rev Contemp Pharmacother* 1995;6:271-85.

57 Ichimiya T, Suhara T, Sudo Y, et al. Serotonin transporter binding in patients with mood disorders: a PET study with [¹¹C](+)McN5652. *Biol Psychiatry* 2002;51:715-22.

58 Innis R, Baldwin R, Sybirska E, Zea Y, et al. Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [¹²³I]CIT. *Eur J Pharmacol* 1991;200:369-70.

59 Karow T, Lang- Roth R, Allgemeine und Spezielle Pharmakologie und Toxikologie 2006, Thomas Karow. 2005

60 Kauppinen TA, Bergstrom KA, Heikman P, Hiltunen J, Ahonen AK. Biodistribution and radiation dosimetry of [¹²³I]ADAM in healthy human subjects: preliminary results. *Eur J Nucl Med Mol Imaging* 2003;30:132-6.

61 Kauppinen T, Koskela A, Diemling M, Keski-Rahkonen A, Sihvola E, Ahonen A. Comparison of manual and automated quantification methods of ¹²³I-ADAM. *Nuklearmedizin* 2005;44:205-12.

62 Kilic F, Murphy DL, Rudnick G. A human serotonin transporter mutation causes constitutive activation of transport activity. *Mol Pharmacol* 2003;21:440-6.

- 63 Kish SJ, Furukawa Y, Chang LJ, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? *Nucl Med Biol* 2005;32:123-8.
- 64 Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. *Neuropsychopharmacology* 2003;28:413-20.
- 65 Kugaya A, Sanacora G, Staley JK, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. *Biol Psychiatry* 2004;56:497-502.
- 66 Kuhn R. Treatment of depressive states with an iminodibenzyl derivative (G 22355). *Schweiz Med Wochenschr* 1957;87:1135-40.
- 67 Kuikka JT, Bergstrom KA, Vanninen E, Laulumaa V, Hartikainen P, Lansimies E. Initial experience with single-photon emission tomography using iodine-123-labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane in human brain. *Eur J Nucl Med* 1993;20:783-6.
- 68 Kuikka JT, Tammela L, Bergstrom KA; Karhunen L, Uusitupa M, Thiihonen J. Effects of ageing on serotonin transporters in healthy females. *Eur J Nucl Med* 2001;28:911-3.
- 69 Lapin IP, Oxenkrug GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. *Lancet* 1969;1:132-6.
- 70 Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [¹²³I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. *Synapse* 1993;13:295-309.
- 71 Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. *J Neurochem* 1993;60:2319-22.
- 72 Lesch KP, Balling U, Gross J, et al. Organization of the human serotonin transporter gene. *J Neural Transm Gen Sect* 1994;95:157-62.
- 73 Lesch KP, Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? *Biol Psychiatry* 1998;44(3):179-92.
- 74 Lin KJ, Yen TC, Wey SP, et al. Characterization of the binding sites for ¹²³I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. *J Nucl Med* 2004;45:673-81.

- 75 Lin KJ, Liu CY, Wey SP, et al. SPECT imaging and whole-body biodistribution with [(123)I]ADAM - a serotonin transporter radiotracer in healthy human subjects. *Nucl Med Biol* 2006;33:193-202.
- 76 Little KY, Kirkman JA, Carroll FI; Breese GR, Duncan GE. [125I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain. *J Neurochem* 1993;61:1996-2006.
- 77 McQueen JK, Wilson H, Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. *Brain Res Mol Brain Res* 1997;45:13-23.
- 78 Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. *Biol Psychiatry* 1998;44:1090-8.
- 79 Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. *Neuropsychopharmacology* 1999;21:99-105.
- 80 Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer (Ed) *Psychopharmacology: the third generation of progress*. New York, Raven Press, 1987, 513-526
- 81 Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. *Depress Anxiety* 1999;9:54-60.
- 82 Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. *Am J Psychiatry* 2001;158:1843-9.
- 83 Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. *Am J Psychiatry* 2004;161:826-35.
- 84 Neumeister A, Pirker W, Willeit M et al. Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. *Biol Psychiatry* 2000;47:158-60.
- 85 Newberg AB, Plossl K, Mozley PD, et al. Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. *J Nucl Med* 2004;45:834-41.

- 86 Newberg AB, Amsterdam JD, Wintering N, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. *J Nucl Med* 2005;46:973-7.
- 87 Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. *Clin Chem* 1994;40:288-95.
- 88 Oya S, Choi SR, Hou C, et al. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. *Nucl Med Biol* 2000;27:249-54.
- 89 Pachmayr F. 99mTechnetium- MIBI- Myokardperfusions- SPECT mit simultaner 153 Gadolinium- Transmissionsmessung zur Schwächungskorrektur Phantommessungen und Beobachtungen an Patientenmessungen zur Abschätzung der Abhängigkeit von klinisch relevanten Störeinflüssen. *Klinik und Poliklinik für Nuklearmedizin der LMU München*. 2004
- 90 Parsey RV, Kegeles LS, Hwang DR, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. *J Nucl Med* 2000;41:1465-77. Erratum in: *J Nucl Med* 2000;41:1946.
- 91 Pirker W, Asenbaum S, Kasper S, et al. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. *J Neural Transm Gen Sect* 1995;100:247-56.
- 92 Pirker W, Asenbaum S, Hauk M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. *J Nucl Med* 2000;41:36-44.
- 93 Plotkin M, Herold N, Franke L, Uebelhack K, Uebelhack R, Amthauer H, Felix R. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression. *J Nucl Med* 2005; 46(Suppl 2):1005.
- 94 Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. *Neuropsychopharmacology* 2000;23:587-90.
- 95 Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. *J Neurochem*. 2000;74:21-33.
- 96 Ramamoorthy S, Bauman AL, Moore KR, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. *Proc Natl Acad Sci USA* 1993;90:2542-6.
- 97 Rapport MM, Green AA, Page IH. Crystalline serotonin. *Science* 1948;108:329-30.

- 98 Rudnick G, Humphreys CJ. Platelet serotonin transporter. *Methods Enzymol* 1992;215:213-24.
- 99 Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. *Biochim Biophys Acta* 1993;1144:249-63.
- 100 Russo AF, Clark MS, Durham PL. Thyroid parafollicular cells. An accessible model for the study of serotonergic neurons. *Mol Neurobiol* 1996;13:257-76.
- 101 Sacher J, Asenbaum S, Klein N, et al. Binding kinetics of ¹²³I [ADAM] in healthy controls: a selective SERT radioligand. *Int J Neuropsychopharmacol* 2006;:1-8
- 102 Schildkraut JJ. The catecholamine hypothesis of affective disorders. A review of supporting evidence. *Int J Psychiatry* 1967;4, 203-17.
- 103 Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. *Prog Neuropsychopharmacol Biol Psychiatry* 2005;29:1074-84.
- 104 Shiue GG, Choi SR, Fang P. N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters. *J Nucl Med* 2003;44:1890-7.
- 105 Sneddon JM. Blood platelets as a model for monoamine-containing neurones. *Prog Neurobiol* 1973;1:151-98.
- 106 Staley JK, Basile M, Flynn DD, Mash DC. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [¹²⁵I]RTI-55: in vitro binding and autoradiographic characterization. *J Neurochem* 1994;62:549-56.
- 107 Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. *Biol Psychiatry* 1998;44:534-49.
- 108 Staley JK, Krishnan-Sarin S, Zoghbi S, et al. Sex differences in [¹²³I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. *Synapse* 2001;41:275-84.
- 109 Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. *Arch Gen Psychiatry* 2003;60:386-91.

- 110 Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry* 2000;157:1552-62.
- 111 Szabo Z, Scheffel U, Suehiro M, et al. Positron emission tomography of 5-HT transporter sites in the baboon brain with [11C]McN5652. *J Cereb Blood Flow Metab* 1995;15:798-805.
- 112 Szabo Z, Kao PF, Scheffel U, et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. *Synapse* 1995;20:37-43.
- 113 Szabo Z, McCann UD, Wilson AA, et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. *J Nucl Med* 2002;46:678-92. Erratum in: *J Nucl Med* 2002;43:744.
- 114 Tauscher J, Pirker W, de Zwaan M, et al. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. *Eur Neuropsychopharmacol* 1999;9:177-9.
- 115 Tauscher J, Pirker W, Willeit M, et al. [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. *Biol Psychiatry* 2001;49:326-32.
- 116 Tork I. Anatomy of the serotonergic system. *Ann N Y Acad Sci*. 1990;600:9-35.
- 117 Uebelhack R, Franke L, Plotkin M, Amthauer H, Felix R. Reduction of the brain 123I-ADAM binding is related to the plasma drug level in amitriptyline treated subjects. *Eur Neuropharmacol* 2004;Suppl 3;14:214-15.
- 118 Uebelhack K, Franke L, Herold N, Plotkin M, Amthauer H, Uebelhack R. 123I-ADAM-SPECT imaging of serotonin transporters in depressed patients- relationship to different aspects of major depression. 8th world congress of biological psychiatry, Wien, 28.06-3.07.05, PO-016.14.
- 119 Uebelhack R, Franke L, Herold N, Plotkin M, Amthauer H, Felix R. Brain and platelet serotonin transporter in humans-correlation between [123I]-ADAM SPECT and serotonergic measurements in platelets. *Neurosci Lett* 2006;406(3):153-8.
- 120 van Dyck CH, Malison RT, Seibyl JP, et al. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. *Neurobiol Aging* 2000;2:497-501.
- 121 van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. *Am J Geriatr Psychiatry* 2002;10:36-43.

- 122 Vercouillie J, Tarkiainen J, Halldin C, et al. Precursor synthesis and radiolabeling of [¹¹C]ADAM: a potent radioligand for the serotonin transporter exploration by PET. *J Labelled Compds Radiopharm* 2001;44:113-20.
- 123 Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. *J Neurosci* 1996;16:2352-64.
- 124 Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. *JAMA* 1996;276:293-90.
- 125 Willeit M, Praschak- Rieder N, Neumeister A, et al. [¹²³I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. *Biol Psychiatry* 2000;47:482-9.
- 126 Wilson AA, Ginovart N, Schmidt M, et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. *J Med Chem* 2000;43:3103-10.
- 127 Yamamoto M, Suhara T, Okubo Y, et al. Age-related decline of serotonin transporters in living human brain of healthy males. *Life Sci* 2002;71:751-7.
- 128 Ye XX, Hwang JJ, Hsieh JF, et al. In vivo quantification by SPECT of [¹²³I] ADAM bound to serotonin transporters in the brains of rabbits. *Nucl Med Biol* 2004;31:995-1003.